Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 4, April, p. 469–477

doi: 10.17219/acem/78025

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Bridging anticoagulation in patients treated with vitamin K antagonists prior to trochanteric and hip fracture surgeries: The current practice

Krzysztof Szklanny1,A,B,C,D, Michał Jakubek1,B,C,D, Katarzyna Zbierska-Rubinkiewicz2,C,D,E, Anetta Undas3,4,A,E,F

1 Department of Orthopedics, St. Lucas Hospital in Tarnów, Poland

2 Department of Vascular Surgery and Endovascular Procedures, John Paul II Hospital, Kraków, Poland

3 Center for Medical Research and Technology, John Paul II Hospital, Kraków, Poland

4 Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland


Background. The strategies of perioperative bridging anticoagulation in orthopedic surgical patients during oral anticoagulation (OAC) therapy with vitamin K antagonists (VKA) vary from center to center.
Objectives. The aim of this single-center study was to assess the risk of bleeding and thromboembolic events (TEs) in bridged patients on VKA who underwent orthopedic surgery due to trochanteric or hip fracture.
Material and Methods. The retrospective study included 64 patients (mean age: 80 years) who received VKA for at least 3 months prior to orthopedic procedure. All subjects were bridged with enoxaparin (40 mg once a day). The control group (n = 69) comprised of age-, sexand procedure-matched patients operated on for the same indications, but with neither a history of VKA therapy nor perioperative bridging anticoagulation.
Results. Severe postoperative bleeding occurred in 19 (29.7%) patients from the VKA group and in 13 (18.8%) controls (p = 0.16). Within the VKA group, intertrochanteric fractures (52.6%) and femoral neck fractures (47.4%) occurred more often in patients with bleeding than other lower extremity fractures (0%; p = 0.03). Severe adverse events (SAEs) were more common in the VKA group than in the controls (12.5% vs 1.5%; p = 0.01). Patients from the VKA group did not differ from the controls in the incidence of TEs (6.3% vs 8.9%; p = 0.31). No intrahospital mortality was documented.
Conclusion. Prophylactic administration of enoxaparin is a common strategy of bridging anticoagulation in a hospital setting. This approach does not seem to be associated with an increase in thromboembolic risk nor higher risk of bleeding in orthopedic patients who received VKA preoperatively.

Key words

anticoagulation, low molecular weight heparin, vitamin K antagonists, bridging therapy, trochanteric and hip neck fracture surgery

References (36)

  1. Marzonlini M, Wynne H. Should patients manage their own oral anticoagulation therapy? Rev Clin Gerontol. 2002;12(4):275–281.
  2. Ashouri F, Al-Jundi W, Patel A, Mangwani J. Management of warfarin anticoagulation in patients with fractured neck of femur. ISRN Hematol. 2011;2011:294628.
  3. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE. Predictors of functional recovery one year following hospital discharge for hip fracture: A prospective study. J Gerontol. 1990;45(3):M101–M107.
  4. Magaziner J, Hawkes W, Hebel JR, et al. Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci. 2000;55(9):M498–M507.
  5. Ho HH, Lau TW, Leung F, Tse HF, Siu CW. Peri-operative management of anti-platelet agents and anti-thrombotic agents in geriatric patients undergoing semi-urgent hip fracture surgery. Osteoporos Int. 2010;21(Suppl 4):573–577.
  6. Morris AH, Zuckerman JD ; American Academy of Orthopaedic Surgeons. National Consensus Conference on Improving the Continuum of Care for Patients with Hip Fracture. J Bone Joint Surg Am. 2002;84-A(4):670–674.
  7. Kapitan-Malinowska B, Bogołowska-Stieblich A. Venous thromboembolic disease [in Polish]. Postępy Nauk Medycznych. 2009;5:345–354.
  8. Oberweis BS, Nukala S, Rosenberg A, et al. Thrombotic and bleeding complications after orthopedic surgery. Am Heart J. 2013;165(3):427–433.
  9. Singh JA, Jensen MR, Harmsen WS, Gabriel SE, Lewallen DG. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. Ann Rheum Dis. 2011;70(12):2082–2088.
  10. Haighton M, Kempen DH, Wolterbeek N, Marting LN, van Dijk M, Veen RM. Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty. J Orthop Surg Res. 2015;10:145.
  11. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–833.
  12. Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Practice of bridging anticoagulation: Guideline adherence and risk factors for bleeding. Neth J Med. 2014;72(3):157–164.
  13. Ghanbari H, Feldman D, Schmidt M, et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2010;33(4):400–406.
  14. Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010;55(21):2376–2382.
  15. Cano O, Osca J, Sancho-Tello MJ, Olague J, Castro JE, Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace. 2011;13:395–401.
  16. Li HK, Chen FC, Rea RF, et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol. 2011;34(7):868–874.
  17. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–1639.
  18. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5):488–494.
  19. Rechenmacher SJ, Fang JC. Bridging anticoagulation: Primum non nocere. J Am Coll Cardiol. 2015;66(12):1392–1403.
  20. Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, et al. Major bleeding as a predictor of mortality in patients with venous thromboembolism: Findings from the RIETE Registry. J Thromb Haemost. 2010;8(6):2575–2577.
  21. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: A meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med. 2013;173(2):132–139.
  22. Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175(7):1163–1168.
  23. Wysokinski WE, McBane RD. Periprocedural bridging management of anticoagulation. Circulation. 2012;126(4):486–490.
  24. Cavalcanti R, Rosenbaum B, Benzel E, Varma N. “Safe period” of anticoagulation withdrawal in patients with mechanical heart valve(s). J Am Coll Cardiol. 2015;65(10):A2035.
  25. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: The use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost. 2010;8(1):107–113.
  26. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: Outcomes and practice patterns at nine hospitals. Am J Med. 2010;123(2):141–150.
  27. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e326S-e350S.
  28. Sircar P, Godkar D, Mahgerefteh S, Chambers K, Niranjan S, Cucco R. Morbidity and mortality among patients with hip fractures surgically repaired within and after 48 hours. Am J Ther. 2007;14(6):508–513.
  29. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. 2000;71(1):47–50.
  30. Tharmarajah P, Pusey J, Keeling D, Willett K. Efficacy of warfarin reversal in orthopedic trauma surgery patients. J Orthop Trauma. 2007;21(1):26–30.
  31. Shiga T, Wajima Z, Ohe Y. Is operative delay associated with increased mortality of hip fracture patients? Systematic review, meta-analysis, and meta-regression. Can J Anaesth. 2008;55(3):146–154.
  32. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition: 2005 update. Br J Haematol. 2006;132:277–285.
  33. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy: Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2000;172(12):600–605.
  34. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(Suppl 6):160S–198S.
  35. Chmielewski D, Górecki A, Kusz D, et al. Zasady profilaktyki żylnej choroby zakrzepowo-zatorowej w ortopedii i traumatologii narządu ruchu (aktualizacja z dnia 18.02.2014). Ortop Traumatol Rehabil. 2014;16:227–239.
  36. Breen DT, Chavalertsakul N, Paul E, Gruen RL, Serpell J. Perioperative complications in patients on low-molecular-weight heparin bridging therapy. ANZ J Surg. 2016;86(3):167–172.